Nebivolol as a potential adjunct therapy for sepsis-induced cardiac dysfunction: evidence from a rat model
Ruveyda Ummugulsum Unal, Onural Ozhan, Elif Sude Balkaya, Azibe Yildiz, Feyzi Dogru, Mehmet Ertugrul Balkar, Ayse Maden, Ayse Yucekaya, Zeynep Kucukakcali, Hakan Parlakpinar · 2026
Read Nebivolol as a potential adjunct therapy for sepsis-induced cardiac dysfunction: evidence from a rat model by Ruveyda Ummugulsum Unal, Onural Ozhan, Elif Sude Balkaya, Azibe Yildiz, Feyzi Dogru, Mehmet Ertugrul Balkar, Ayse Maden, Ayse Yucekaya, Zeynep Kucukakcali, Hakan Parlakpinar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13527123.txt.
Description
Ruveyda Unal and nine co-authors test a heart drug against sepsis damage in rats in a 2026 study. Sepsis, the body's runaway answer to infection, often bruises the heart through stress chemicals and inflammation. Nebivolol, a gentle beta blocker with antioxidant side talents, had protected other organs in earlier work.
Thirty-two rats were split into healthy, drug-only, septic, and septic-plus-drug groups, with sepsis induced by gut puncture. The drug slowed the racing heart, eased a conduction delay, and softened oxidative and tissue damage in the heart. But blood pressure, swelling, and vessel injury stayed unmoved. The authors call it local protection worth probing further, not a cure.
Catalog record
| CREATOR | Ruveyda Ummugulsum Unal, Onural Ozhan, Elif Sude Balkaya, Azibe Yildiz, Feyzi Dogru, Mehmet Ertugrul Balkar, Ayse Maden, Ayse Yucekaya, Zeynep Kucukakcali, Hakan Parlakpinar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |